Pulsenmore Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Elazar Sonnenschein
- Full Time Employees
- 63
- Sector
- Technology services
- Industry
- Packaged software
- Address
- 8 Omarim Street Omer Israel
- IPO Date
- Jun 15, 2021
- Website
- pulsenmore.com
- Similar Companies
- Business
- Pulsenmore Ltd. develops and commercializes innovative self-scan ultrasound systems for remote clinical assessment, primarily focused on transforming prenatal care. The company's core offering, the Pulsenmore ES, integrates a portable ultrasound device that securely docks with a patient's personal smartphone, utilizing a dedicated mobile application to guide users through diagnostic imaging procedures for fetal monitoring. This system then facilitates the secure transmission and display of these ultrasound images via a cloud-based software platform, enabling healthcare professionals to remotely review and interpret the scans. Pulsenmore aims to expand access to high-quality maternal health services, particularly in underserved regions, by enabling at-home monitoring under physician supervision. The company has received significant regulatory milestones, including FDA De Novo marketing authorization in November 2025 for its home-use prenatal ultrasound platform in the United States, paving the way for a phased U.S. launch in early 2026. Pulsenmore also offers solutions for remote follicular monitoring in IVF treatments and is actively exploring additional medical applications for its home ultrasound technology. The company was established in 2014 and maintains its base of operations in Omer, Israel.
Company News
Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer
Pulsenmore Expands Its Fertility Platform into the UK
Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring
Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026
Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026
Pulsenmore Expands Its Home Ultrasound Activity in Israel: Ichilov Adopts the Technology, Expanding Access to At-Home Pregnancy Monitoring
Pulsenmore Receives Second AI Grant Within One Month: Israel Innovation Authority Approves $1.27 Million for SmartScan AI Program
Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor
Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States
Pulsenmore Announces Full Year 2025 Financial Results and Webcast
Pulsenmore Announces Full Year 2025 Earnings Conference Call
Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.